Funding Announcement for bioAffinity Technologies
In a significant move for the biotechnology sector, WallachBeth Capital LLC has announced a $2.66 million registered direct offering and concurrent private placement for bioAffinity Technologies, Inc. (NASDAQ: BIAF). This funding is aimed at supporting the company’s mission to advance noninvasive cancer detection, a critical area in healthcare innovation.
Details of the Securities Purchase Agreement
Under the terms of the securities purchase agreement, institutional investors will acquire 2,048,294 shares of common stock at a price of $1.30 per share. In addition, the agreement involves a concurrent private placement of warrants, allowing the purchase of up to 2,662,782 shares at an exercise price of $1.50 per share. These warrants will become exercisable once the company’s stockholders approve their exercise, granting investors a strategic advantage for future stock acquisition.
Expected Closing and Financial Implications
The offering's closing is anticipated to occur shortly, provided that all customary conditions are satisfied. The gross proceeds from this offering are projected to be approximately $2.66 million, excluding the potential earnings from warrant exercises. However, it is important to note that this sum does not account for placement agent fees and other related expenses that WallachBeth Capital will incur.
The Role of WallachBeth Capital
As the sole placement agent for this significant offering, WallachBeth Capital is uniquely positioned to guide bioAffinity Technologies through this pivotal financial phase. Their extensive experience in the market will be invaluable as the company navigates the implications of this investment.
Legal and Regulatory Considerations
All shares issued in this offering will fall under an effective shelf registration statement on Form S-3 previously approved by the U.S. Securities and Exchange Commission (SEC). The prospectus supplement detailing the terms of this registered offering will soon be available on the SEC’s website, allowing for transparency in the investment process.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. stands at the forefront of innovative biotechnology solutions, focusing on early detection of cancer through noninvasive testing methods. This approach not only enhances the precision of diagnostics but also expands access to critical early-stage cancer detection, potentially saving countless lives through timely medical intervention.
About WallachBeth Capital LLC
WallachBeth Capital specializes in offering a comprehensive range of capital markets and investment banking services tailored to the healthcare industry. Their expertise encompasses various financial transactions including initial public offerings, follow-on issues, and private equity placements. The firm’s dedication to connecting corporate clients with preeminent institutions enhances the efficacy of capital raising in the biotech sector.
Frequently Asked Questions
What is the purpose of the $2.66 million offering?
The funds are intended to support bioAffinity Technologies in enhancing its noninvasive cancer detection capabilities.
Who are the primary investors in this offering?
The offering is backed by institutional investors interested in advancing healthcare technology.
Why are warrants included in this offering?
Warrants provide investors with an opportunity to purchase additional shares, ensuring they can benefit from future growth.
When is the expected closing date for the offering?
The closing is expected to occur soon, contingent upon customary closing conditions being met.
What does this offering signify for the future of bioAffinity Technologies?
This funding opportunity underlines the confidence investors have in bioAffinity's potential and its commitment to revolutionizing cancer diagnostics.
